Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

NCT02581345 is registered in ClinicalTrials.gov with Momenta Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02581345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Lead sponsor
Momenta Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2015
Completion date
April 4, 2017
Enrollment
572 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

chronic plaque psoriasis, psoriasis